Hirva Mamdani

1.9k total citations · 1 hit paper
102 papers, 1.0k citations indexed

About

Hirva Mamdani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hirva Mamdani has authored 102 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Hirva Mamdani's work include Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (27 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Hirva Mamdani is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (27 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Hirva Mamdani collaborates with scholars based in United States, Canada and Japan. Hirva Mamdani's co-authors include Shadia I. Jalal, Ahmed Bilal Khalid, Sandro Matosevic, Gregory A. Durm, Melissa L. Johnson, Rachel E. Sanborn, Shahid Ahmed, Tony Mok, Samantha Armstrong and Alexander I. Spira and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Hirva Mamdani

98 papers receiving 1.0k citations

Hit Papers

Immunotherapy in Lung Cancer: Current Landscape and Futur... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immunotherapy in Lung Cancer: Current Landscape and Future Directions
    2022 214 citations Hirva Mamdani, Ahmed Bilal Khalid et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hirva Mamdani United States 19 597 436 364 143 131 102 1.0k
Federica Biello Italy 20 634 1.1× 418 1.0× 267 0.7× 154 1.1× 292 2.2× 56 994
Satoru Kitazono Japan 23 1.0k 1.7× 833 1.9× 349 1.0× 108 0.8× 252 1.9× 92 1.5k
Erin Larkins United States 14 637 1.1× 441 1.0× 286 0.8× 116 0.8× 162 1.2× 28 937
Tindara Franchina Italy 19 749 1.3× 633 1.5× 487 1.3× 98 0.7× 311 2.4× 60 1.3k
Bo H. Chao United States 17 872 1.5× 833 1.9× 375 1.0× 132 0.9× 205 1.6× 49 1.3k
Catherine A. Shu United States 19 1.0k 1.7× 1.0k 2.3× 265 0.7× 161 1.1× 190 1.5× 64 1.5k
Ecaterina E. Dumbrava United States 17 647 1.1× 218 0.5× 379 1.0× 185 1.3× 194 1.5× 115 1.0k
Zhanhong Xie China 18 761 1.3× 519 1.2× 227 0.6× 164 1.1× 172 1.3× 60 1.1k
Elvire Pons‐Tostivint France 13 468 0.8× 351 0.8× 238 0.7× 86 0.6× 134 1.0× 47 764
Hao‐Wen Sim Australia 17 326 0.5× 327 0.8× 364 1.0× 90 0.6× 299 2.3× 73 931

Countries citing papers authored by Hirva Mamdani

Since Specialization
Citations

This map shows the geographic impact of Hirva Mamdani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirva Mamdani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirva Mamdani more than expected).

Fields of papers citing papers by Hirva Mamdani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirva Mamdani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirva Mamdani. The network helps show where Hirva Mamdani may publish in the future.

Co-authorship network of co-authors of Hirva Mamdani

This figure shows the co-authorship network connecting the top 25 collaborators of Hirva Mamdani. A scholar is included among the top collaborators of Hirva Mamdani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirva Mamdani. Hirva Mamdani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clarke, Jeffrey, George R. Simon, Hirva Mamdani, et al.. (2025). Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Nature Communications. 16(1). 93–93. 7 indexed citations
2.
Choucair, Khalil, Andrew Elliott, Matthew J. Oberley, et al.. (2025). Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma. PubMed. 4(1). e000551–e000551.
3.
4.
Beltran, Himisha, Prantesh Jain, Erin L. Schenk, et al.. (2025). 2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers. Annals of Oncology. 36. S1367–S1367.
5.
Elliott, Andrew, Wendy Cozen, Evanthia T. Roussos Torres, et al.. (2024). Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8526–8526. 1 indexed citations
6.
7.
Kim, Richard D., Hirva Mamdani, Minal Barve, et al.. (2024). A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.. Journal of Clinical Oncology. 42(16_suppl). 2621–2621. 1 indexed citations
8.
Trendowski, Matthew R., Donovan Watza, Christine M. Lusk, et al.. (2024). Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 33(9). 1220–1228. 3 indexed citations
9.
Choudhury, Noura J., Himisha Beltran, Erin L. Schenk, et al.. (2024). OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S32–S33. 4 indexed citations
10.
Khalid, Ahmed Bilal, Christos Fountzilas, Heather Burney, et al.. (2024). A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma. Frontiers in Oncology. 14. 1435056–1435056. 1 indexed citations
11.
Heyza, Joshua, Christopher K. Yunker, Lisa Polin, et al.. (2023). ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe. NAR Cancer. 5(1). zcac045–zcac045. 4 indexed citations
12.
13.
Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations
14.
15.
Richardson, Gary, Raed Moh’d Taiseer Al-Rajabi, Dipesh Uprety, et al.. (2023). A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors. Cancers. 15(9). 2553–2553. 2 indexed citations
16.
Khan, Husain Yar, Misako Nagasaka, Yiwei Li, et al.. (2022). Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers. Cancer Research Communications. 2(5). 342–352. 21 indexed citations
17.
Azar, Ibrahim, Stephani C. Wang, Dawn Lombardo, et al.. (2022). Preferences and Attitudes of Cardiologists in Management of Patients with Cancer. SHILAP Revista de lepidopterología. 3(1). 279–286. 2 indexed citations
18.
Johnson, Melissa L., Anthony B. El-Khoueiry, Navid Hafez, et al.. (2021). Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 27(16). 4521–4530. 45 indexed citations
19.
Nagasaka, Misako, Vijendra K. Singh, Yasmine Baca, et al.. (2021). The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 52–59. 21 indexed citations
20.
Bravo, Gabriela, Misako Nagasaka, Peizhi Ma, et al.. (2019). P2.01-100 Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S680–S680. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Federica Biello Breakdown of academic impact, for papers by Satoru Kitazono Breakdown of academic impact, for papers by Erin Larkins Breakdown of academic impact, for papers by Tindara Franchina Breakdown of academic impact, for papers by Bo H. Chao Breakdown of academic impact, for papers by Catherine A. Shu Breakdown of academic impact, for papers by Ecaterina E. Dumbrava Breakdown of academic impact, for papers by Zhanhong Xie Breakdown of academic impact, for papers by Elvire Pons‐Tostivint Breakdown of academic impact, for papers by Hao‐Wen Sim
Rankless by CCL
2026